Laying the Groundwork to Measure the Impact of Decentralized Clinical Trials (DCTs)
The Tufts CSDD Roundtable took place in November, and on behalf of Veristat, I was honored to participate in this invite-only program. It is part of our company’s DNA to stay ahead of the driving forces in the industry so that we can best serve as a knowledgeable partner for our clients, most of whom are small to mid size organizations involved in rare diseases and novel therapies. Ken Getz, the Tufts CSDD team, my pharmaceutical and CRO colleagues and I came prepared to engage in a frank and open dialogue on quantifying the value proposition of decentralized clinical trial (DCT) deployments.